Free Trial

Gyre Therapeutics (GYRE) Earnings Date, Estimates & Call Transcripts

Gyre Therapeutics logo
$4.72 +0.41 (+9.51%)
As of 12:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gyre Therapeutics Earnings Summary

Gyre Therapeutics posted Q3 2026 earnings on November 5, 2026, reporting an EPS of $0.04, which topped the consensus estimate of -$0.15 by $0.19. Quarterly revenue was reported to be $32.93 million, above analysts' expectations of $28.40 million. With a trailing EPS of -$0.20, Gyre Therapeutics' earnings are expected to grow next year, from ($0.61) to ($0.47) per share.

Latest Q3
Earnings Date
Nov. 5Estimated
Consensus EPS
(Nov. 5)
-$0.15
Actual EPS
(Nov. 5)
$0.04 Beat By $0.19
Actual Revenue
(Nov. 5)
$32.93M

Q3 2026 Earnings Resources

Get Gyre Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

GYRE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GYRE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Gyre Therapeutics Analyst EPS Estimates & Company Guidance

Low, high and average are individual analyst estimates we track. Guidance columns are the company's own outlook, and the revenue estimate was recorded when that guidance was issued.

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Revenue GuidanceRevenue Estimate at Guidance
Q1 20261$0.09$0.09$0.09
Q2 20262-$0.09-$0.08-$0.09
Q3 20262-$0.10-$0.07-$0.09
Q4 20262-$0.11-$0.05-$0.08
FY 20267-$0.21-$0.11-$0.16

Gyre Therapeutics Earnings History by Quarter

Report Date
0 Results
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026-$0.15$0.04+$0.19$0.0030$28.40M$32.93M
8/7/2026Q2 2026-$0.0567-$0.12 -$0.0633-$0.12$26.49M$29.11M
3/12/2026Q4 2025$0.08$0.04 -$0.04-$0.02$36.30M$37.20M
8/11/2025Q2 2025$0.03$0.02 -$0.01$0.04$30.80M$26.77M
5/9/2025Q1 2025$0.03$0.03-$0.0265$28.40M$22.06M
3/17/2025Q4 2024$0.04$0.01 -$0.03$0.02$23.50M$27.87M

Gyre Therapeutics Earnings - Frequently Asked Questions

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earning data on Thursday, November 5, 2026. Learn more on GYRE's earnings history.

Gyre Therapeutics updated its FY 2026 earnings guidance on Friday, November, 6th. The company issued revenue guidance of $100.5 million-$111.0 million, compared to the consensus revenue estimate of $109.6 million.

In the previous quarter, Gyre Therapeutics (NASDAQ:GYRE) reported $0.04 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.15) by $0.19. Learn more on analysts' earnings estimate vs. GYRE's actual earnings.

Gyre Therapeutics' earnings report can be found in their filing with the SEC.
View SEC filing

Gyre Therapeutics (NASDAQ:GYRE) has a recorded annual revenue of $116.59 million.

Gyre Therapeutics (NASDAQ:GYRE) has a recorded net income of $5.03 million. GYRE has generated -$0.20 earnings per share over the last four quarters.

Gyre Therapeutics' earnings are expected to grow from ($0.61) per share to ($0.47) per share in the next year.


Earnings data for NASDAQ:GYRE is sourced from Fiscal.ai, with the most recent quarter reported on 11/5/2026. New results are added as companies report their earnings.
From Our Partners